Biodesix chair exercises RSUs into 1,361 shares
Biodesix Inc. chairman John Patience exercised restricted stock units into common shares on March 31, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Biodesix Inc. chairman John Patience exercised restricted stock units into common shares on March 31, 2026. He converted 1,361 RSUs into 1,361 shares of common stock at an exercise price of $0.00 per share. Following the transactions, he directly holds 24,022 common shares and 4,082 RSUs, with additional indirect holdings through Patience Enterprises LP, the John Patience Living Trust, and his spouse.
Insider Trade Summary
1,361 shares exercised/converted
Exercise
2 txns
Insider
PATIENCE JOHN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,361 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,361 | $0.00 | $0.00 |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 4,082 contracts (Direct);
Common Stock — 24,022 shares (Direct);
Common Stock — 107,664 shares (Indirect, By Patience Enterprises LP);
Common Stock — 241,480 shares (Indirect, By John Patience Living Trust dated 7/23/1993);
Common Stock — 2,649 shares (Indirect, By Spouse)
Footnotes (4)
- F1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
- F2. The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F3. The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).
- F4. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Key Figures
RSUs exercised: 1,361 units
Exercise price: $0.00 per share
Direct common shares after transaction: 24,022 shares
+5 more
8 metrics
RSUs exercised
1,361 units
Converted into common stock on March 31, 2026
Exercise price
$0.00 per share
RSU conversion into common stock
Direct common shares after transaction
24,022 shares
Held directly by John Patience after March 31, 2026
RSUs outstanding after transaction
4,082 units
Restricted stock units held by John Patience
Indirect shares via Patience Enterprises LP
107,664 shares
Held by Patience Enterprises LP; Patience is sole general partner
Indirect shares via Living Trust
241,480 shares
Held by John Patience Living Trust dated July 23, 1993
Indirect shares via spouse
2,649 shares
Held by spouse as indirect ownership
Total derivative exercises in filing
1,361 shares
Exercise or conversion of derivative security per summary
Key Terms
Restricted Stock Units, pecuniary interest, beneficial ownership, Section 16, +1 more
5 terms
Restricted Stock Units financial
"Each restricted stock unit (the "RSU") represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
pecuniary interest financial
"disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein"
beneficial ownership financial
"shall not be deemed an admission of beneficial ownership of all of the reported shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"for purposes of Section 16 or for any other purpose"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
vesting financial
"These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Biodesix (BDSX) chairman John Patience report?
John Patience reported exercising 1,361 restricted stock units into 1,361 shares of Biodesix common stock at an exercise price of $0.00. This was a derivative exercise, not an open-market purchase or sale, and reflects routine equity compensation activity.
What are the vesting terms for John Patience’s Biodesix RSUs reported in this filing?
The restricted stock units vest in four substantially equal installments on March 31, June 30, September 30, and December 31, 2026. Vesting is generally subject to John Patience’s continued service with Biodesix and the RSUs have no stated expiration date under these terms.
AI-generated analysis. How Rhea-AI works. Not financial advice.
